Major Scope

  •  Lung Cancer
  •  Colorectal Cancer
  •  Pancreatic Cancer
  •  Breast Cancer
  •  Prostate Cancer
  •  Liver Cancer
  •  Leukemia
  •  Bladder Cancer
  •  Kidney Cancer
  •  Endometrial Cancer
  •  Oncology Case Reports
  •  Radiation Therapy

Abstract

Citation: Clin Oncol. 2018;3(1):1481.DOI: 10.25107/2474-1663-v3-id1481

Investigation of Fiducial Marker Migration during the Treatment of Bladder Cancer with Image-Guided Radiation Therapy

Yulin Song, Ming Yan, Boris Mueller and Borys Mychalczak

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, USA
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, USA

*Correspondance to: Yulin Song 

 PDF  Full Text Research Article | Open Access

Abstract:

Surgically implanted fiducial markers are widely used in the treatment of prostate, lung, and breast cancers with Image-Guided Radiation Therapy (IGRT). Fiducial markers are typically nonmigrating gold seeds with various dimensions for different site applications. To prevent markers from migrating in implanted soft tissue, their surfaces are cross-cut using a special knurling process. Implanted fiducial markers are felt to constitute a more reliable reference coordinate system than surrounding bony landmarks for a moving target and are used for point-based image registration. Studies have shown that fiducial markers are safe, stable, and can provide superior tumor tracking and targeting capability during both treatment planning and treatment delivery. At our institution, implanted fiducial markers are now being used for target volume localization in bladder cancer patients treated with IGRT. In this paper, we present our initial experience with this novel treatment procedure in terms of fiducial marker migration.

Keywords:

Bladder cancer; IGRT; IMRT; OBI; Fiducial marker

Cite the Article:

Song Y, Yan M, Mueller B, Mychalczak B. Investigation of Fiducial Marker Migration during the Treatment of Bladder Cancer with Image-Guided Radiation Therapy. Clin Oncol. 2018; 3: 1481.

Journal Basic Info

  • Impact Factor: 3.231**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
  • PubMed NLM ID: 101705590

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Outcome of Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia Following Single Agent Induction with Hypomethylation
 PDF  Full Text
Dosimetric Comparison of IMRT, Hybrid IMRT and Hybrid VMAT for Early Stage Right-Sided Breast Cancer
 Abstract  PDF  Full Text
View More...